Success Story: NIW Approval for a Biomedical Science Researcher Advancing Cancer Epigenetics
Client’s Testimonial:
"Working with the Chen immigration group has been a very smooth experience. Putting the petition together takes effort and time, but I was very happy both with the final product and the communication throughout the process. Thank you for your help!”
On April 11th, 2026, we received another EB-2 NIW (National Interest Waiver) approval for a PhD Candidate in the Field of Biomedical Science (Approval Notice).
General Field: Biomedical Science
Position at the Time of Case Filing: PhD Candidate
Approval Notice Date: April 11th, 2026
Processing Time: 2 months, 21 days (Premium Processing Upgrade Requested)
Case Summary:
The approval of this I-140 NIW petition highlights how a carefully framed case can present a young researcher’s work as nationally important even without an unusually long publication history. In this matter, we showed that the client, a biomedical science researcher, had already built a strong record of achievement in cancer genomics and precision medicine, and that his future work carried clear value for the United States.
Research Leadership and National Impact
The client’s proposed endeavor focused on developing advanced assays for epigenetic profiling to identify oncogenic molecular mechanisms across hematological and solid tumors, with the goal of supporting new therapeutic targets and helping inhibit cancer progression. We emphasized that this work was not important merely because it addressed cancer in the abstract, but because it centered on highly specialized tools that can improve how researchers detect, interpret, and act on molecular changes driving disease. That framing helped show both substantial merit and national importance under the NIW standard.
The client’s qualifications supported that narrative. He had authored 5 peer-reviewed journal articles, including 1 co-first-authored paper and 1 accepted article, along with 2 preprints. His work had received >180 citations. We did not treat those numbers as self-evidently sufficient. Instead, we showed how an adjudicator could view them as objective signs of independent reliance, especially because several papers had been cited at unusually high rates for their publication year and field. We also highlighted funding support connected to major national research priorities, including support from the National Heart, Lung, and Blood Institute, , the National Cancer Institute, the National Human Genome Research Institute, the National Institutes of Health, and others. That evidence helped demonstrate that the client’s research area had already attracted meaningful institutional confidence.
Expert Endorsements
The case also included 2 recommendation letters from experts familiar with the client’s work. These letters were helpful because they did more than offer general praise. Their support reinforced that the client was well-positioned to continue advancing research with implications for cancer treatment and biomedical innovation in the United States. One expert noted:
“For these reasons, I view [Client’s] research as vital to strengthening the scientific and medical infrastructure of the U.S.”
NIW Approval and Outlook
By showing not only that the client had produced high-quality work, but also that other researchers and major funding bodies had already relied on and invested in that work, we were able to present a persuasive NIW case. We are delighted by this approval and look forward to the client’s continued contributions to cancer research and the development of new precision medicine tools in the United States.